November/December 2019 | Medical Editors' Page
The Future of Retina
Allen C. Ho, MD, and Robert L. Avery, MD
November/December 2019 | Visually Speaking
Optic Disc Melanocytoma
Kumar Saurabh, MD, MS, and Rupak Roy, MD, MS
November/December 2019 | Medical Retina
Silicone Oil Droplets After Bevacizumab Intravitreal Injection
Although this rare occurrence is not harmful, patients and clinicians should be educated on the potential sequelae following anti-VEGF treatment.
Eric K. Chin, MD, and David R.P. Almeida, MD, MBA, PhD
November/December 2019 | Medical Retina
A Choroidal Mass: An Unusual Metastasis With Unusual Treatment
Choroidal metastasis is rare in individuals with renal cancer.
Jordana G. Fein, MD, MS; Heeral R. Shah, MD; Komal B. Desai, MD; Taylor Lind; and Uma Desai
November/December 2019 | Features
Phase 3 in Retina: The Trials to Know
This review will help you understand where several potentially important studies stand.
Michael Ammar, MD, and Jason Hsu, MD
November/December 2019 | Features
Reframing the Retina Pipeline
By moving beyond thinking of the pipeline as which drug is in which phase, we can take a fresh perspective on therapeutic candidates in development.
Pravin U. Dugel, MD
November/December 2019 | Features
The Neovascular AMD Pipeline
What might the future of wet AMD therapy look like?
Priyatham (Prithu) S. Mettu, MD
November/December 2019 | Features
Looking to the Future of Gene Therapy in Ophthalmology
In a symposium ahead of the AAO Annual Meeting, speakers updated attendees on the status of the field.
Kourous A. Rezaei, MD
November/December 2019 | Features
The Uveitis Pipeline
Take a look at what's next in uveitis.
Steven Yeh, MD
November/December 2019 | Features
The Future of Home-Based OCT for Retina Patients
Products in the pipeline could improve outcomes and reduce burdens on patients and physicians.
John B. Miller, MD; and Rebecca Zeng, BA; With Sidebar Commentary by Judy E. Kim, MD
November/December 2019 | Features
Gene Therapy Approach Demonstrated Safety With Durable Effect in Interim Wet AMD Trial Results
A dose-dependent increase in protein expression was noted in interim results, with lasting effect in higher doses.
Jeffrey S. Heier, MD; Allen C. Ho, MD; and Robert L. Avery, MD
November/December 2019 | Features
Intravitreal In-Office Anti-VEGF Gene Therapy
An update on ADVM-022 and the OPTIC trial.
Szilárd Kiss, MD
November/December 2019 | Meeting Minutes
ARDS Meeting Minutes
Yale L. Fisher, MD; and Hugo Quiroz-Mercado, MD; Summarized by Luis A. Gonzalez, MD, MPH
November/December 2019 | Meeting Minutes
VBS Fellows' Program: Primer on Inherited Retinal Diseases
A lecture by Stephen Tsang, MD, PhD, explored progress in this burgeoning field.
James Lin, MD
November/December 2019 | 5Q Interview
5Q With S.K. Steven Houston III, MD
S.K. Steven Houston III, MD